Pacific Bio (NASDAQ: PACB) reported Q1 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $19.4 million versus the consensus estimate of $24.54 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.